Pan Arab Journal of Oncology - Arab Medical Association Against ...

More documents

Recommendations

Info

instructions for the authors Pan Arab Journal of Oncology | vol 6; issue 1 | March 2013AbstractAbstracts are limited to 250 words and must appear after the titlepage. Abstracts must be formatted according to the followingheadings: (1) Purpose, (2) Patients and methods (or materials andmethods, similar heading), (3) Results, and (4) Conclusion. Authorsmay use design instead of Patients and methods in abstracts ofReview Articles. Comments and Controversies, Editorials andCorrespondence do not require abstracts.TextThe body of the manuscript should be written as concisely aspossible and must not exceed the manuscript category wordlimits described herein. All pages of a submission should benumbered and double-spaced. Helvetica and Arial at 12pt sizeare the recommended fonts for all text (see Figures section foracceptable fonts for figures). The Journal adheres to the styleguidelines set forth by the International Committee of MedicalJournal Editors.ReferencesReferences must be listed and numbered after the body text in theorder in which they are cited in the text. They should be doublespacedand should appear under the heading “REFERENCES.”Abbreviations of medical periodicals should conform to thoseused in the latest edition of Index Medicus and on MEDLINE.The «List of Journals Indexed in Index Medicus» includes thelatest abbreviations. Inclusive page numbers must be cited inthe reference. When a reference is for an abstract or supplement,it must be identified as such in parentheses at the end of thereference. Abstract and supplement numbers should be provided,if applicable. When a reference is a personal communication,unpublished data, a manuscript in preparation, or a manuscriptsubmitted but not in press, it should be included in parentheses inthe body of the text, and not cited in the reference list. Publishedmanuscripts and manuscripts that have been accepted and arepending publication should be cited in the reference list.Reference Styleº Journal article with one, two, or three authors1. Dolan ME, Pegg AE: O6-Benzylguanine and its role inchemotherapy. Clin Cancer Res 8:837-847, 1997º Journal article with more than three authors2. Knox S, Hoppe RT, Maloney D, et al: Treatment of cutaneousT-cell lymphoma with chimeric anti-CD4 monoclonal antibody.Blood 87:893-899, 1996º Journal article in press (manuscript has been accepted forpublication)3. Scadden DT, Schenkein DP, Bernstein Z, et al: Combinedimmunotoxin and chemotherapy for AIDS-related non-Hodgkin’slymphoma. Cancer (in press)º Supplement4. Brusamolino E, Orlandi E, Morra E, et al: Analysis of long-termwww.amaac.org
esults and prognostic factors among 138 patients with advancedHodgkin’s disease treated with the alternating MOPP/ABVDchemotherapy. Ann Oncol 5:S53-S57, 1994 (suppl 2)º Book with a single author5. Woodruff R: Symptom Control in Advanced Cancer. Victoria,Australia, Asperula Pty Ltd, 1997, pp 65-69º Book with multiple authors6. Iverson C, Flanagin A, Fontanarosa PB, et al: American MedicalAssociation Manual of Style (ed 9). Baltimore, MD, Williams &Wilkins, 1998º Chapter in a multiauthored book with editors7. Seykora JT, Elder DE: Common acquired nevi and dysplasticnevi as precursor lesions and risk markers of melanoma, inKirkwood JM (ed): Molecular Diagnosis and Treatment ofMelanoma. New York, NY, Marcel Dekker, 1998, pp 55-86º Abstract8. Bardia A, Wang AH, Hartmann LC, et al: Physical activity andrisk of postmenopausal breast cancer defined by hormone receptorstatus and histology: A large prospective cohort study with 18years of follow up. J Clin Oncol 24:49s, 2006 (suppl; abstr 1002)9. Kaplan EH, Jones CM, Berger MS: A phase II, open-label,multicenter study of GW572016 in patients with trastuzumabrefractory metastatic breast cancer. Proc Am Soc Clin Oncol22:245, 2003 (abstr 981)º Conference/meeting presentation10. Dupont E, Riviere M, Latreille J, et al: Neovastat: Aninhibitor of angiogenesis with anti-cancer activity. Presented atthe American Association of Cancer Research Special Conferenceon Angiogenesis and Cancer, Orlando, FL, January 24-28, 1998º Internet resource11. Health Care Financing Administration: Bureau of datamanagement and strategy from the 100% MEDPAR inpatienthospital fiscal year 1994: All inpatients by diagnosis related groups,6/95 update. http://www.hcfa.gov/a1194drg.txtº Digital Object Identifier (DOI)12. Small EJ, Smith MR, Seaman JJ, et al: Combined analysisof two multicenter, randomized, placebo-controlled studies ofpamidronate disodium for the palliation of bone pain in men withmetastatic prostate cancer. J Clin Oncol 10.1200/JCO.2003.05.147FiguresFigures must be cited in the order they appear in the text usingArabic numerals. Figures should be submitted in a seperatedocumen. Figure legends are required for all article types. Figurelegends must not exceed 55 words per figure and should be writtenbelow the figure.Images may be embedded in word or Power Point files.TablesTables must be cited in the order in which they appear in thetext using Arabic numerals. The table’s legend may include anypertinent notes and must include definitions of all abbreviationsand acronyms that have been used in the table. Tables submittedwith multiple parts will be renumbered. Tables should be submittedin a seperate document. Legends must not exceed 55 words pertable and should be written above the figure.Appendices/AcknowledgmentsAppendices and acknowledgments will appear in the print versionof the article.Language: Appropriate use of the English language is encouragedfor publication in the Journal.5. Post-acceptance InformationCopyright FormCorresponding authors must provide unique e-mail addressfor each contributing author at manuscript submission. Uponacceptance of the manuscript, each author will receive an e-mailinvitation to sign a statement confirming that the manuscriptcontains no material for which publication would violate anycopyright or other personal or proprietary right of any person orentity. Manuscripts will not be published until each author hascompleted the form.Page ProofsCorresponding author will receive proofs and must carefullyreview them for data and typesetting errors. Corrections to proofsmust be returned by e-mail, fax, or mail within 1 week. Thecorresponding author is responsible for collecting and submittingall author corrections into a single submission. Publication maybe delayed if proofs are not returned by the publisher’s deadline.The Editor-in-Chief must approve all major alterations, whichmay delay publication of the manuscript.º Government Announcement/Publication13. Miller BA, Ries CAG, Hankey BF, et al (eds): Cancer StatisticsReview: 1973-1989. Bethesda, MD, National Cancer Institute,NIH publication No. 92-2789, 1992º ASCO Educational Book14. Benson AB 3rd: Present and future role of prognostic andpredictive markers for patients with colorectal cancer. Am SocClin Oncol Ed Book 187-190, 2006www.amaac.org Pan Arab Journal of Oncology | vol 6; issue 1 | March 2013 < 49
Page 1 and 2: Pan Arab Journal of OncologyISSN: 2
Page 3 and 4: editorial board
Page 5 and 6: international advisory board
Page 7 and 8: Thank you for all contributors, aut
Page 9 and 10: notes
Page 11 and 12: to presence of positive family hist
Page 15 and 16: The average of the volume of bladde
Page 18 and 19: original article Pan Arab Journal
Page 22 and 23: original article
Page 34 and 35: original article 2 cm> 3 - ≤ 20 m
Page 36 and 37: original article 50%was observed in
Page 39 and 40: neck cancer. Mol Imaging Biol 2003;
Page 41 and 42: and IMLN negative. Three patients h
Page 45 and 46: www.amaac.org Pan Arab Journal of O
Page 47 and 48: MissionE a s t e r n P r o v i n c
Page 49: objectives & scope of the PAJO
Page 54: Give them the energyto keep up with

Pan Arab Journal of Oncology - Arab Medical Association Against ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?